Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire August 7, 2024

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Business Wire August 6, 2024

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Business Wire July 24, 2024

Clinical Data from Open-Label Extension LILAC-1(TM) and LILAC-2(TM) Studies Evaluating Long-Term Safety and Efficacy of DAYBUE(TM) (trofinetide) in Patients with Rett Syndrome Published in Med

Business Wire July 18, 2024

Acadia Pharmaceuticals Presents DAYBUE(TM) (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Business Wire June 18, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 17, 2024

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

Business Wire May 15, 2024

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire May 9, 2024

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Business Wire May 8, 2024

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Business Wire April 29, 2024

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Business Wire April 24, 2024

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Business Wire April 22, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 19, 2024

Acadia Pharmaceuticals Presents New DAYBUE(TM) (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Business Wire April 17, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

ACCESS Newswire April 5, 2024

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Business Wire April 2, 2024

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 1, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

ACCESS Newswire April 1, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

ACCESS Newswire March 28, 2024

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation

Newsfile March 27, 2024